Badalona Major Depressive Disorder Database Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01446692
First received: September 28, 2011
Last updated: January 11, 2012
Last verified: January 2012

September 28, 2011
January 11, 2012
November 2011
Not Provided
Description of the antidepressant strategies switches [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Number and type of treatment changes including combination, switch, or augmentation strategies.
Same as current
Complete list of historical versions of study NCT01446692 on ClinicalTrials.gov Archive Site
  • Health care resource utilization [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Health care costs [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Hamilton Depression Rating Scale [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Medication possession rate to evaluate adherence [ Time Frame: 18 months ] [ Designated as safety issue: No ]
  • Referral to psychiatrist office [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Badalona Major Depressive Disorder Database Study
Therapeutic Strategies for the Management of Patients With Major Depressive Disorder (MDD) and Suboptimal Response to Antidepressant Drugs in Primary Care: the Badalona Database Study

A retrospective study using a data base of anonymized medical records. The purpose of the study is to examine the different therapeutic strategies for the management of patients with major depressive disorder (MDD) and suboptimal response to antidepressant drugs in primary care

Therapeutic strategies for the management of patients with major depressive disorder (MDD) and suboptimal response to antidepressant drugs in primary care: the Badalona database study

Observational
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Primary care clinic

Major Depressive Disorder
Not Provided
  • Patients with suboptimal response
  • Patients with symptomatic remission
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2260
January 2012
Not Provided

Inclusion Criteria:

  • An International Classification of Primary Care (ICPC-2) or DSM-IV-TR diagnosis for major depressive disorder (MDD)
  • At least 8 weeks of antidepressant treatment during the identification period of 01 January 2008 - 31 December 2009
  • 18 months of enrollment with medical and pharmacy records after index episode date
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT01446692
NIS-NES-XXX-2011/2
No
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP